These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 7295080)

  • 21. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of hemodialysis on duodenal and gastric mucosal changes in uremic patients.
    Var C; Gültekin F; Candan F; Türkay C; Sencan M; Içağasioğlu S; Dökmetaş S; Topçu S; Içli F; Var F; Eğilmez R
    Clin Nephrol; 1996 May; 45(5):310-4. PubMed ID: 8738662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis.
    Chuang CK; Lin SP; Chen HH; Chen YC; Wang TJ; Shieh WH; Wu CJ
    Clin Chim Acta; 2006 Feb; 364(1-2):209-16. PubMed ID: 16087168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phagocytic polymorphonuclear function in patients with progressive uremia and the effect of acute hemodialysis.
    Mahajan S; Kalra OP; Asit KT; Ahuja G; Kalra V
    Ren Fail; 2005; 27(4):357-60. PubMed ID: 16060119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gel-filtration on psoriasic and uremic serum and dialysis fluid.
    Lamperi S; Buoncristiani U; Carozzi S; Cozzari M; Icardi A; Trasforini D
    Artif Organs; 1981; 4 Suppl():156-9. PubMed ID: 7295083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Examination of lymphokines in patients with hemodialysis (author's transl)].
    Löcsey L; Kálmán K; Hauck M; Kakuk G
    Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of middle molecules in uremic patients.
    Wu ZG; Cai ZH; Lu ZN; Liao LT; Zhu SQ
    Chin Med J (Engl); 1985 Feb; 98(2):115-20. PubMed ID: 3922688
    [No Abstract]   [Full Text] [Related]  

  • 31. Our experience with combined hemodialysis-hemoperfusion treatment in chronic uremia.
    Splendiani G; Albano V; Tancredi M; Daniele M; Pignatelli F
    Biomater Artif Cells Artif Organs; 1987; 15(1):175-81. PubMed ID: 3449135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.
    Bourgoignie J; Klahr S; Bricker NS
    J Clin Invest; 1971 Feb; 50(2):303-11. PubMed ID: 5540168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiovascular risk markers in hemodialysis].
    Urso S; Milone F; Garozzo M; Cannavò ME; Biondi A; Battaglia G
    G Ital Nefrol; 2004; 21 Suppl 30():S212-6. PubMed ID: 15750988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients.
    Khedmat H; Ahmadzad-Asl M; Amini M; Lessan-Pezeshki M; Einollahi B; Pourfarziani V; Naseri MH; Davoudi F
    Transplant Proc; 2007 May; 39(4):1003-7. PubMed ID: 17524875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
    Maduell F
    Nefrologia; 2005; 25 Suppl 2():15-8. PubMed ID: 16050396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Middle molecular weight substances in the cerebrospinal fluid of uremic patients.
    Sperschneider H; Spustova V; Stein G; Dzurik R
    Clin Nephrol; 1982 Jun; 17(6):298-302. PubMed ID: 7105504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What remains of the "middle molecule" hypothesis today?
    Brunner H; Mann H
    Contrib Nephrol; 1985; 44():14-39. PubMed ID: 3886282
    [No Abstract]   [Full Text] [Related]  

  • 38. Middle molecules in uraemia.
    Fürst P; Asaba M; Gordon A; Zimmerman L; Bergström J
    Proc Eur Dial Transplant Assoc; 1975; 11():417-26. PubMed ID: 1105558
    [No Abstract]   [Full Text] [Related]  

  • 39. Loss of phospholipids asymmetry in red blood cells contributes to anemia in uremic patients.
    Kong QY; Wu X; Li J; Peng WX; Ye R; Lindholm B; Wang T
    Adv Perit Dial; 2001; 17():58-60. PubMed ID: 11510298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Separation and characterization of uremic metabolites in biologic fluids: a screening approach to the definition of uremic toxins.
    Gordon A; Berström J; Fürst P; Zimmerman L
    Kidney Int Suppl; 1975 Jan; (2):45-51. PubMed ID: 1057692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.